Skip to main content
Erschienen in: Herz 3/2022

03.05.2022 | Koronare Herzerkrankung | CME

Myokardiale Revaskularisation

Kontroverse um den nicht-invasiven und den invasiven Ischämienachweis

verfasst von: Luise Gaede, Johannes Blumenstein, Prof. Dr. med. Helge Möllmann

Erschienen in: Herz | Ausgabe 3/2022

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die myokardiale Revaskularisation bei Patienten mit chronischem Koronarsyndrom wird – bis auf einige Ausnahmen – in Abhängigkeit von der myokardialen Ischämie entschieden. Hierbei ergibt sich aus den aktuell vorliegenden Daten, dass Patienten von einer Revaskularisation profitieren, wenn eine Ischämie in über 10 % des Myokards vorliegt. Entsprechend sollten alle Patienten vor der Koronarangiographie einen Ischämietest erhalten, der diese Frage beantworten kann. Um auch bei den Patienten, die vorher keinen eindeutigen Ischämienachweis aufwiesen (z. B. aufgrund von diskrepanten Befunden), eine auf wissenschaftlichen Daten fundierte Empfehlung zur Revaskularisation treffen zu können, sollte hier im Rahmen der Koronarangiographie die Messung der hämodynamischen Signifikanz der Koronarstenosen mit einer Lumendiameterreduktion von 50 % oder mehr erfolgen. Eine Entscheidung zur Revaskularisation auf Basis der hämodynamischen Signifikanz zeigte sich in mehreren Studien von Vorteil für den Patienten.
Literatur
1.
Zurück zum Zitat Ibanez B, James S, Agewall S et al (2018) 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation the task force for the management of acute myocardial infarction. Eur Heart J 39:119–177 CrossRef Ibanez B, James S, Agewall S et al (2018) 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation the task force for the management of acute myocardial infarction. Eur Heart J 39:119–177 CrossRef
2.
Zurück zum Zitat Roffi M, Patrono C, Collet J‑P et al (2016) 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 37:1101–1106 CrossRef Roffi M, Patrono C, Collet J‑P et al (2016) 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 37:1101–1106 CrossRef
3.
Zurück zum Zitat Neumann FJ, Sousa-Uva M, Ahlsson A et al (2019) 2018 ESC/EACTS guidelines on myocardial revascularization. Eur Heart J 40:87–165 CrossRef Neumann FJ, Sousa-Uva M, Ahlsson A et al (2019) 2018 ESC/EACTS guidelines on myocardial revascularization. Eur Heart J 40:87–165 CrossRef
4.
Zurück zum Zitat Knuuti J, Wijns W, Saraste A et al (2020) 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J 41:407–477 CrossRef Knuuti J, Wijns W, Saraste A et al (2020) 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J 41:407–477 CrossRef
5.
Zurück zum Zitat Frye R, August P, Brooks M, Hardison R (2009) A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med 360:2503–2515 CrossRef Frye R, August P, Brooks M, Hardison R (2009) A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med 360:2503–2515 CrossRef
6.
Zurück zum Zitat Boden W, O’Rourke R, Teo KK et al (2007) Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 356:1503–1516 CrossRef Boden W, O’Rourke R, Teo KK et al (2007) Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 356:1503–1516 CrossRef
7.
Zurück zum Zitat Shaw LJ, Berman DS, Maron DJ et al (2008) Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden results from the clinical outcomes utilizing revascularization and aggressive drug evaluation (COURAGE) trial nuclear substudy. Circulation 117:1283–1291 CrossRef Shaw LJ, Berman DS, Maron DJ et al (2008) Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden results from the clinical outcomes utilizing revascularization and aggressive drug evaluation (COURAGE) trial nuclear substudy. Circulation 117:1283–1291 CrossRef
8.
Zurück zum Zitat Hachamovitch R, Rozanski A, Shaw LJ et al (2011) Impact of ischaemia and scar on the therapeutic benefit derived from myocardial revascularization vs. medical therapy among patients undergoing stress-rest myocardial perfusion scintigraphy. Eur Heart J 32:1012–1024 CrossRef Hachamovitch R, Rozanski A, Shaw LJ et al (2011) Impact of ischaemia and scar on the therapeutic benefit derived from myocardial revascularization vs. medical therapy among patients undergoing stress-rest myocardial perfusion scintigraphy. Eur Heart J 32:1012–1024 CrossRef
9.
Zurück zum Zitat Knuuti J, Ballo H, Juarez-Orozco LE et al (2018) The performance of non-invasive tests to rule-in and rule-out significant coronary artery stenosis in patients with stable angina: a meta-analysis focused on post-test disease probability. Eur Heart J 39:3322–3330 CrossRef Knuuti J, Ballo H, Juarez-Orozco LE et al (2018) The performance of non-invasive tests to rule-in and rule-out significant coronary artery stenosis in patients with stable angina: a meta-analysis focused on post-test disease probability. Eur Heart J 39:3322–3330 CrossRef
10.
Zurück zum Zitat Greenwood JP, Maredia N, Younger JF et al (2012) Cardiovascular magnetic resonance and single-photon emission computed tomography for diagnosis of coronary heart disease (CE-MARC): a prospective trial. Lancet 379:453–460 CrossRef Greenwood JP, Maredia N, Younger JF et al (2012) Cardiovascular magnetic resonance and single-photon emission computed tomography for diagnosis of coronary heart disease (CE-MARC): a prospective trial. Lancet 379:453–460 CrossRef
11.
Zurück zum Zitat Nagel E, Greenwood JP, McCann GP et al (2019) Magnetic resonance perfusion or fractional flow reserve in coronary disease. N Engl J Med 380:2418–2428 CrossRef Nagel E, Greenwood JP, McCann GP et al (2019) Magnetic resonance perfusion or fractional flow reserve in coronary disease. N Engl J Med 380:2418–2428 CrossRef
12.
Zurück zum Zitat Maron DJ, Hochman JS, Reynolds HR et al (2020) Initial invasive or conservative strategy for stable coronary disease. N Engl J Med 382:1395–1407 CrossRef Maron DJ, Hochman JS, Reynolds HR et al (2020) Initial invasive or conservative strategy for stable coronary disease. N Engl J Med 382:1395–1407 CrossRef
13.
Zurück zum Zitat Maron D, Hochman J, Brien S et al (2018) International study of comparative health effectiveness with medical and INvasive approaches (ISCHEMIA) trial: rationale and design. Am Heart J 201:124–135 CrossRef Maron D, Hochman J, Brien S et al (2018) International study of comparative health effectiveness with medical and INvasive approaches (ISCHEMIA) trial: rationale and design. Am Heart J 201:124–135 CrossRef
14.
Zurück zum Zitat Pijls NHJ, De Bruyne B, Peels K et al (1996) Measurement of fractional flow reserve to assess the functional severity of coronary-artery stenoses. N Engl J Med 334:1703–1708 CrossRef Pijls NHJ, De Bruyne B, Peels K et al (1996) Measurement of fractional flow reserve to assess the functional severity of coronary-artery stenoses. N Engl J Med 334:1703–1708 CrossRef
15.
Zurück zum Zitat Fischer JJ, Samady H, Mcpherson JA et al (2002) Comparison between visual assessment and quantitative angiography versus fractional flow reserve for native coronary narrowings of moderate severity. Am J Cardiol 90:210–215 CrossRef Fischer JJ, Samady H, Mcpherson JA et al (2002) Comparison between visual assessment and quantitative angiography versus fractional flow reserve for native coronary narrowings of moderate severity. Am J Cardiol 90:210–215 CrossRef
16.
Zurück zum Zitat Pijls NHJ, van Schaardenburgh P, Manoharan G et al (2007) Percutaneous coronary intervention of functionally nonsignificant stenosis. 5‑year follow-up of the DEFER study. J Am Coll Cardiol 49:2105–2111 CrossRef Pijls NHJ, van Schaardenburgh P, Manoharan G et al (2007) Percutaneous coronary intervention of functionally nonsignificant stenosis. 5‑year follow-up of the DEFER study. J Am Coll Cardiol 49:2105–2111 CrossRef
17.
Zurück zum Zitat Zimmermann FM, Ferrara A, Johnson NP et al (2015) Deferral vs. performance of percutaneous coronary intervention of functionally non-significant coronary stenosis: 15-year follow-up of the DEFER trial. Eur Heart J 36:3182–3188 CrossRef Zimmermann FM, Ferrara A, Johnson NP et al (2015) Deferral vs. performance of percutaneous coronary intervention of functionally non-significant coronary stenosis: 15-year follow-up of the DEFER trial. Eur Heart J 36:3182–3188 CrossRef
18.
Zurück zum Zitat Tonino PAL, Fearon WF, De Bruyne B et al (2010) Angiographic versus functional severity of coronary artery stenoses in the FAME study. Fractional flow reserve versus angiography in multivessel evaluation. J Am Coll Cardiol 55:2816–2821 CrossRef Tonino PAL, Fearon WF, De Bruyne B et al (2010) Angiographic versus functional severity of coronary artery stenoses in the FAME study. Fractional flow reserve versus angiography in multivessel evaluation. J Am Coll Cardiol 55:2816–2821 CrossRef
19.
Zurück zum Zitat De Bruyne B, Pijls NHJ, Kalesan B et al (2012) Fractional flow reserve–guided PCI versus medical therapy in stable coronary disease. N Engl J Med 367:991–1001 CrossRef De Bruyne B, Pijls NHJ, Kalesan B et al (2012) Fractional flow reserve–guided PCI versus medical therapy in stable coronary disease. N Engl J Med 367:991–1001 CrossRef
21.
Zurück zum Zitat Smits PC, Abdel-Wahab M, Neumann F‑J et al (2017) Fractional flow reserve–guided multivessel angioplasty in myocardial infarction. N Engl J Med 376:1234–1244 CrossRef Smits PC, Abdel-Wahab M, Neumann F‑J et al (2017) Fractional flow reserve–guided multivessel angioplasty in myocardial infarction. N Engl J Med 376:1234–1244 CrossRef
22.
Zurück zum Zitat Engstrøm T, Kelbæk H, Helqvist S et al (2015) Complete revascularisation versus treatment of the culprit lesion only in patients with ST-segment elevation myocardial infarction and multivessel disease (DANAMI‑3 - PRIMULTI): An open-label, randomised controlled trial. Lancet 386:665–671 CrossRef Engstrøm T, Kelbæk H, Helqvist S et al (2015) Complete revascularisation versus treatment of the culprit lesion only in patients with ST-segment elevation myocardial infarction and multivessel disease (DANAMI‑3 - PRIMULTI): An open-label, randomised controlled trial. Lancet 386:665–671 CrossRef
23.
Zurück zum Zitat Zimmermann FM, Omerovic E, Fournier S et al (2019) Fractional flow reserve-guided percutaneous coronary intervention vs . medical therapy for patients with stable coronary lesions : meta-analysis of individual patient data. Eur Heart J 40:180–186 CrossRef Zimmermann FM, Omerovic E, Fournier S et al (2019) Fractional flow reserve-guided percutaneous coronary intervention vs . medical therapy for patients with stable coronary lesions : meta-analysis of individual patient data. Eur Heart J 40:180–186 CrossRef
24.
Zurück zum Zitat Götberg M, Christiansen EH, Gudmundsdottir IJ et al (2017) Instantaneous wave-free ratio versus fractional flow reserve to guide PCI. N Engl J Med 376:1813–1823 CrossRef Götberg M, Christiansen EH, Gudmundsdottir IJ et al (2017) Instantaneous wave-free ratio versus fractional flow reserve to guide PCI. N Engl J Med 376:1813–1823 CrossRef
25.
Zurück zum Zitat Davies JE, Sen S, Dehbi H‑M et al (2017) Use of the instantaneous wave-free ratio or fractional flow reserve in PCI. N Engl J Med 376:1824–1834 CrossRef Davies JE, Sen S, Dehbi H‑M et al (2017) Use of the instantaneous wave-free ratio or fractional flow reserve in PCI. N Engl J Med 376:1824–1834 CrossRef
26.
Zurück zum Zitat Svanerud J, Ahn J, Jeremias A et al (2018) Validation of a novel non-hyperaemic index of coronary artery stenosis severity : the resting full-cycle ratio ( VALIDATE RFR ) study. EuroIntervention 14:806–814 CrossRef Svanerud J, Ahn J, Jeremias A et al (2018) Validation of a novel non-hyperaemic index of coronary artery stenosis severity : the resting full-cycle ratio ( VALIDATE RFR ) study. EuroIntervention 14:806–814 CrossRef
27.
Zurück zum Zitat Rioufol G, Dérimay F, Roubille F et al (2021) Fractional flow reserve to guide treatment of patients with multivessel coronary artery disease. J Am Coll Cardiol 78:1875–1885 CrossRef Rioufol G, Dérimay F, Roubille F et al (2021) Fractional flow reserve to guide treatment of patients with multivessel coronary artery disease. J Am Coll Cardiol 78:1875–1885 CrossRef
30.
Zurück zum Zitat Farkouh M, Domanski M, Sleeper L et al (2012) Strategies for multivessel revascularization in patients with diabetes. N Engl J Med 367:2375–2384 CrossRef Farkouh M, Domanski M, Sleeper L et al (2012) Strategies for multivessel revascularization in patients with diabetes. N Engl J Med 367:2375–2384 CrossRef
31.
Zurück zum Zitat Thuijs DJFM, Kappetein AP, Serruys PW et al (2019) Percutaneous coronary intervention versus coronary artery bypass grafting in patients with three-vessel or left main coronary artery disease: 10-year follow-up of the multicentre randomised controlled SYNTAX trial. Lancet 394:1325–1334 CrossRef Thuijs DJFM, Kappetein AP, Serruys PW et al (2019) Percutaneous coronary intervention versus coronary artery bypass grafting in patients with three-vessel or left main coronary artery disease: 10-year follow-up of the multicentre randomised controlled SYNTAX trial. Lancet 394:1325–1334 CrossRef
32.
Zurück zum Zitat Spertus J, Jones P, Maron D et al (2020) Health-status outcomes with invasive or conservative care in coronary disease. N Engl J Med 382:1408–1419 CrossRef Spertus J, Jones P, Maron D et al (2020) Health-status outcomes with invasive or conservative care in coronary disease. N Engl J Med 382:1408–1419 CrossRef
33.
Zurück zum Zitat Werner GS, Martin-yuste V, Hildick-smith D et al (2018) Interventional cardiology a randomized multicentre trial to compare revascularization with optimal medical therapy for the treatment of chronic total coronary occlusions. Eur Heart J 39:2484–2493 CrossRef Werner GS, Martin-yuste V, Hildick-smith D et al (2018) Interventional cardiology a randomized multicentre trial to compare revascularization with optimal medical therapy for the treatment of chronic total coronary occlusions. Eur Heart J 39:2484–2493 CrossRef
Metadaten
Titel
Myokardiale Revaskularisation
Kontroverse um den nicht-invasiven und den invasiven Ischämienachweis
verfasst von
Luise Gaede
Johannes Blumenstein
Prof. Dr. med. Helge Möllmann
Publikationsdatum
03.05.2022
Verlag
Springer Medizin
Erschienen in
Herz / Ausgabe 3/2022
Print ISSN: 0340-9937
Elektronische ISSN: 1615-6692
DOI
https://doi.org/10.1007/s00059-022-05110-0

Weitere Artikel der Ausgabe 3/2022

Herz 3/2022 Zur Ausgabe

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.